Janssen Pharma Gets FDA Approval for Lung Cancer Drug
May 21 2021 - 2:10PM
Dow Jones News
By Kimberly Chin
Janssen Pharmaceutical Cos. has won regulatory approval for its
non-small cell lung cancer drug.
The U.S. Food and Drug Administration approved Rybrevant, the
first treatment for adult patients for a type of lung cancer that
has specific genetic mutations. The agency also approved
Guardant360 CDx, a part of Guardant Health Inc., as a companion
diagnostic to Rybrevant.
Janssen has received priority review and breakthrough therapy
designation for the Rybrevant treatment.
Janssen Pharmaceutical is a part of Johnson & Johnson.
Write to Kimberly Chin at kimberly.chin@wsj.com
(END) Dow Jones Newswires
May 21, 2021 13:55 ET (17:55 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Guardant Health (NASDAQ:GH)
Historical Stock Chart
From Mar 2024 to Apr 2024
Guardant Health (NASDAQ:GH)
Historical Stock Chart
From Apr 2023 to Apr 2024
